Long-term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus

Vaccine

Volumn 36, Issue 23, 2018, Pages 3301-3307

  Mok, C C ^a   Ho, L Y ^a   To, C H ^a  

^a TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

Efficacy; Immunogenicity; Long term; Lupus; Vaccination

Indexed keywords

MYCOPHENOLATE MOFETIL; PREDNISOLONE; TACROLIMUS; VIRUS ANTIBODY; WART VIRUS VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; PRIORITY JOURNAL; RISK FACTOR; SEROCONVERSION; SYSTEMIC LUPUS ERYTHEMATOSUS; VACCINATION; VACCINE IMMUNOGENICITY; ADOLESCENT; ALPHAPAPILLOMAVIRUS; BLOOD; IMMUNOLOGY; PATHOGENICITY;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; ANTIBODIES, VIRAL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; IMMUNOGENICITY, VACCINE; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 85046117220     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2018.04.056     Document Type: Article

References (36)

1. de Sanjosé S, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2017 Sep 6. pii: S1521-6934(17)30133-5. doi: 10.1016/j.bpobgyn.2017.08.015. [Epub ahead of print].
2. Erickson, B.K., Alvarez, R.D., Huh, W.K., Human papillomavirus: what every provider should know. Am J Obstet Gynecol 208 (2013), 169–175.
3. Carter, J.R., Ding, Z., Rose, B.R., HPV infection and cervical disease: a review. Aust N Z J Obstet Gynaecol 51 (2011), 103–108.
4. Grein, I.H., Groot, N., Lacerda, M.I., Wulffraat, N., Pileggi, G., HPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should know. Pediatr Rheumatol Online J, 14, 2016, 12.
5. Tam, L.S., Chan, A.Y., Chan, P.K., Chang, A.R., Li, E.K., Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 50 (2004), 3619–3625.
6. Tam, L.S., Chan, P.K., Ho, S.C., et al. Natural history of cervical papilloma virus infection in systemic lupus erythematosus - a prospective cohort study. J Rheumatol 37 (2010), 330–340.
7. Santana, I.U., Gomes Ado, N., Lyrio, L.D., Rios Grassi, M.F., Santiago, M.B., Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. Clin Rheumatol 30 (2011), 665–672.
8. Zard, E., Arnaud, L., Mathian, A., et al. Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature. Autoimmun Rev 13 (2014), 730–735.
9. Lu, B., Kumar, A., Castellsagué X., Giuliano, A.R., Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis, 11, 2011, 13.
10. Future, I.I., Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007), 1915–1927.
11. Garland, S.M., Hernandez-Avila, M., Wheeler, C.M., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 (2007), 1928–1943.
12. Block, S.L., Nolan, T., Sattler, C., et al. Protocol 016 Study Group. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118 (2006), 2135–2145.
13. Muñoz, N., Manalastas, R. Jr, Pitisuttithum, P., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 373 (2009), 1949–1957.
14. Luna, J., Plata, M., Gonzalez, M., et al. Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women. PLoS One, 8, 2013, e83431.
15. Nygård, M., Saah, A., Munk, C., et al. Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine. Clin Vaccine Immunol 22 (2015), 943–948.
16. Ferris, D.G., Samakoses, R., Block, S.L., et al. 4-valent human papillomavirus (4vHPV) vaccine in pre-adolescents and adolescents after 10 years. Pediatrics, 140, 2017 pii: e20163947.
17. Mok, C.C., Ho, L.Y., Fong, L.S., To, C.H., Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 72 (2013), 659–664.
18. Tan, E.M., Cohen, A.S., Fries, J.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25 (1982), 1271–1277.
19. Opalka, D., Matys, K., Bojczuk, P., et al. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol 17 (2010), 818–827.
20. Brown, D.R., Garland, S.M., Ferris, D.G., et al. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin 7 (2011), 230–238.
21. Buyon, J.P., Petri, M.A., Kim, M.Y., et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 142 (2005), 953–962.
22. Petri, M., Hellmann, D., Hochberg, M., Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 19 (1992), 53–59.
23. Heijstek, M.W., Scherpenisse, M., Groot, N., Wulffraat, N.M., Van Der Klis, F.R., Immunogenicity of the bivalent human papillomavirus vaccine in adolescents with juvenile systemic lupus erythematosus or juvenile dermatomyositis. J Rheumatol 40 (2013), 1626–1627.
24. Soybilgic A, Onel KB, Utset T, Alexander K, Wagner-Weiner L. Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years. Pediatr Rheumatol Online J. 2013 Aug 7;11:29. doi: 10.1186/1546-0096-11-29. eCollection 2013.
25. Dhar, J.P., Essenmacher, L., Dhar, R., Magee, A., Ager, J., Sokol, R.J., The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus. Vaccine 35 (2017), 2642–2646.
26. Praditpornsilpa, K., Kingwatanakul, P., Deekajorndej, T., et al. Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV. V and VD. Nephrol Dial Transplant 32 (2017), 132–136.
27. Nelson, D.R., Neu, A.M., Abraham, A., Amaral, S., Batisky, D., Fadrowski, J.J., Immunogenicity of human papillomavirus recombinant vaccine in children with CKD. Clin J Am Soc Nephrol 11 (2016), 776–784.
28. Kumar, D., Unger, E.R., Panicker, G., Medvedev, P., Wilson, L., Humar, A., Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. Am J Transplant 13 (2013), 2411–2417.
29. Kahn, J.A., Xu, J., Kapogiannis, B.G., Sleasman, J.W., Brief report: antibody responses to quadrivalent HPV vaccination in HIV-infected young women as measured by total IgG and competitive luminex immunoassay. J Acquir Immune Defic Syndr 75 (2017), 241–245.
30. Giacomet, V., Penagini, F., Trabattoni, D., et al. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine 32 (2014), 5657–5661.
31. Hidalgo-Tenorio, C., Ramírez-Taboada, J., Gil-Anguita, C., et al. Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM). AIDS Res Ther, 14, 2017, 34, 10.1186/s12981-017-0160-0 eCollection 2017.
32. MacIntyre, C.R., Shaw, P., Mackie, F.E., et al. Immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children. Vaccine 34 (2016), 4343–4350.
33. Gardasil (human papillomavirus quadrivalent [types 6, 11, 16, 18] vaccine, recombinant): product information and supporting documents. Food and Drug Administration. https://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/ucm179549.htm. [Assessed October 16, 2017].
34. Andreoli, L., Bertsias, G.K., Agmon-Levin, N., et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 76 (2017), 476–485.
35. Caulfield, M.J., Shi, L., Wang, S., et al. Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice. Hum Vaccine 3 (2007), 139–145.
36. Geier, D.A., Geier, M.R., Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database. Immunol Res 65 (2017), 46–54.